ANCA-associated glomerulonephritis/systemic vasculitis in childhood: clinical features-outcome

Pediatr Nephrol. 2012 Oct;27(10):1911-20. doi: 10.1007/s00467-012-2198-5. Epub 2012 May 31.

Abstract

Background: Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis and systemic vasculitis (AAGNV) is uncommon in childhood.

Methods: This is a retrospective study of AAGNV cases diagnosed over a 13-year period in a tertiary pediatric nephrology department.

Results: Thirteen cases of AAGNV were identified: seven Wegener granulomatosis (WG) and six microscopic polyangiitis (MPA). Acute renal failure/nephrotic range proteinuria (NRP) was found in 77 % of the patients (4 with WG, all with MPA). Eleven (85 %) patients showed necrotizing glomerulonephritis (NGN), with ≥50 % crescents identified in nine patients (69 %) (4 with WG, 5 with MPA). Treatment with methylprednisolone, cyclophosphamide and plasma exchange resulted in extra-renal remission and antibody reduction in all patients and renal function improvement/stabilization in 77 % of the patients. Three patients, all without oliguria at presentation and few sclerotic lesions, had normal renal function at follow-up. Chronic kidney disease (CKD) stages 2 and 3-4 were observed in four (WG) and three (MPA) patients, respectively. Three patients (23 %) developed end stage renal disease: two were MPA patients with severe presentation (markedly impaired glomerular filtration rate, oliguria, NRP, crescentic NGN, glomerular sclerosis) and one was a WG patient with extensive interstitial fibrosis/tubular atrophy.

Conclusions: Severe renal involvement was more common in children with MPA than WG. Treatment with methylprednisolone, cyclophosphamide and plasma exchange induced extra-renal remission/serological response and renal function improvement/stabilization. Markedly decreased GFR, oliguria, NRP, and chronic glomerular lesions at presentation were predictors of poor outcome.

MeSH terms

  • Acute Kidney Injury / immunology
  • Adolescent
  • Age Factors
  • Antibodies, Antineutrophil Cytoplasmic / blood*
  • Child
  • Cyclophosphamide / administration & dosage
  • Disease Progression
  • Drug Therapy, Combination
  • England
  • Female
  • Glomerular Filtration Rate
  • Glomerulonephritis / immunology*
  • Glomerulonephritis / pathology
  • Glomerulonephritis / physiopathology
  • Glomerulonephritis / therapy
  • Glucocorticoids / administration & dosage
  • Granulomatosis with Polyangiitis / complications
  • Granulomatosis with Polyangiitis / immunology*
  • Granulomatosis with Polyangiitis / pathology
  • Granulomatosis with Polyangiitis / physiopathology
  • Granulomatosis with Polyangiitis / therapy
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Kidney / drug effects
  • Kidney / immunology*
  • Kidney / pathology
  • Kidney / physiopathology
  • Kidney Failure, Chronic / immunology
  • Male
  • Methylprednisolone / administration & dosage
  • Microscopic Polyangiitis / complications
  • Microscopic Polyangiitis / immunology*
  • Microscopic Polyangiitis / pathology
  • Microscopic Polyangiitis / physiopathology
  • Microscopic Polyangiitis / therapy
  • Plasma Exchange
  • Proteinuria / immunology
  • Pulse Therapy, Drug
  • Renal Insufficiency, Chronic / immunology
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Glucocorticoids
  • Immunosuppressive Agents
  • Cyclophosphamide
  • Methylprednisolone